RU2007123797A - Предотвращение формирования и/или стабилизации тромбов - Google Patents
Предотвращение формирования и/или стабилизации тромбов Download PDFInfo
- Publication number
- RU2007123797A RU2007123797A RU2007123797/14A RU2007123797A RU2007123797A RU 2007123797 A RU2007123797 A RU 2007123797A RU 2007123797/14 A RU2007123797/14 A RU 2007123797/14A RU 2007123797 A RU2007123797 A RU 2007123797A RU 2007123797 A RU2007123797 A RU 2007123797A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- antibody
- formation
- fxii
- trypsin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Использование, по меньшей мере, одного антитела и/или одного ингибитора для ингибирования фактора коагуляции XII и предотвращения формирования и/или стабилизации тромбов и предотвращения, таким образом, внутрипросветного роста трехмерного тромба.
2. Использование по п.1, в котором указанное антитело представляет собой антитело анти-FXII.
3. Использование по п.1, в котором указанное антитело представляет собой ингибитор активизации FXII.
4. Использование по п.1, в котором указанный ингибитор представляет собой ингибитор протеазы.
5. Использование по п.1, в котором указанный ингибитор представляет собой ингибитор серин-протеазы.
6. Использование по п.3, в котором указанный ингибитор протеазы выбран из группы, содержащей ингибитор AT III, ангиотензин, ингибитор преобразования фермента, ингибитор С1, апротинин, ингибитор протеазы альфа-1, антиболевое средство ([(S)-1-карбокси-2-фенилэтил]-карбамоил-L-аргинал-L-вал-аргинал) ацетат Z-про-про-альдегид-диметил, DX88, леупептин, ингибиторы пролил олигопептидазы, такие как Fmoc-Ala-Pyr-CN, ингибитор корн-трипсина, мутанты бычьего панкреатического ингибитора трипсина, экотин, YAP (желтый одиночный белок антикоагулянта) и ингибитор-V трипсина семени тыквы и изоингибитор семени тыквы.
7. Использование антитела и/или ингибитора согласно любому из пп.1-4 в медицине.
8. Использование антитела и/или ингибитора по любому из пп.1-4 при изготовлении лекарственных средств.
9. Использование антитела и/или ингибитора по любому из пп.1-4 для лечения или профилактики условия или нарушений, связанных с формированием венозного или артериального тромба, особенно инсульт или инфаркт миокарда, воспаление, активация комплемента, фибринолиз, ангиогенез и/или болезни, связанные с вызванным FXII формированием кинина, такие как наследственная болезнь Квинке, бактериальные инфекции легкого, инфекции трипаносомы, гипотензивный шок, панкреатит, болезнь Шагаса или суставная подагра.
10. Фармацевтический препарат, содержащий, по меньшей мере, одно антитело и/или один ингибитор, который подходит для ингибирования фактора XII и который предотвращает формирование и/или стабилизацию патологических тромбов.
11. Препарат по п.8, в котором указанное антитело представляет собой антитело анти-FXII.
12. Препарат по п.8, в котором указанное антитело ингибирует активацию FXII.
13. Препарат по п.8, в котором указанный ингибитор представляет собой ингибитор протеазы.
14. Препарат по п.8, в котором указанное ингибитор представляет собой ингибитор серин-протеазы.
15. Препарат по п.10, в котором указанное ингибитор протеазы выбран из использования по п.3, в котором указанный ингибитор протеазы выбран из группы, содержащей ингибитор AT III, ангиотензин, ингибитор преобразования фермента, ингибитор С1, апротинин, ингибитор протеазы альфа-1, антиболевое средство ([(S)-1-карбокси-2-фенилэтил]-карбамоил-L-аргинал-L-вал-аргинал) ацетат Z-про-про-альдегид-диметил, DX88, леупептин, ингибиторы пролил олигопептидазы, такие как Fmoc-Ala-Pyr-CN, ингибитор корн-трипсина, мутанты бычьего панкреатического ингибитора трипсина, экотин, YAP (желтый одиночный белок антикоагулянта) и ингибитор-V трипсина семени тыквы и изоингибитор семени тыквы.
16. Использование фактора XII в качестве антитромбического средства ингибированным фактором XII, по меньшей мере, одним антителом и/или одним ингибитором и, следовательно, предотвращение формирования и/или стабилизации тромбов или роста тромба.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04030593.0 | 2004-12-23 | ||
| EP04030593 | 2004-12-23 | ||
| PCT/EP2005/013714 WO2006066878A1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007123797A true RU2007123797A (ru) | 2009-01-10 |
| RU2514878C2 RU2514878C2 (ru) | 2014-05-10 |
Family
ID=34927953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007123797/14A RU2514878C2 (ru) | 2004-12-23 | 2005-12-20 | Предотвращение образования и/или стабилизации тромбов |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8119137B2 (ru) |
| EP (2) | EP1830924B1 (ru) |
| JP (1) | JP5118492B2 (ru) |
| KR (1) | KR101277097B1 (ru) |
| CN (1) | CN101102819A (ru) |
| AU (1) | AU2005318464B2 (ru) |
| BR (1) | BRPI0519349A8 (ru) |
| CA (1) | CA2591786C (ru) |
| DK (1) | DK1830924T3 (ru) |
| ES (1) | ES2407965T3 (ru) |
| MX (1) | MX2007006997A (ru) |
| PL (1) | PL1830924T3 (ru) |
| RU (1) | RU2514878C2 (ru) |
| WO (1) | WO2006066878A1 (ru) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| EP2311432B1 (en) | 2002-06-07 | 2014-12-24 | Dyax Corporation | Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| SI2386310T1 (sl) | 2002-08-28 | 2019-03-29 | Dyax Corp. | Metode za ohranjanje organov in tkiv |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| WO2008098720A1 (en) * | 2007-02-12 | 2008-08-21 | Csl Behring Gmbh | Therapeutic application of kazal-type serine protease inhibitors |
| AU2008288772A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2215256A1 (en) * | 2007-10-22 | 2010-08-11 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| EP2145900A1 (en) | 2008-07-15 | 2010-01-20 | CSL Behring GmbH | Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation |
| EP2103311A1 (en) | 2008-03-20 | 2009-09-23 | CSL Behring GmbH | The calcium sensor STIM1 is essential for pathological thrombus formation |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| EP2269597A1 (en) | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
| US9150864B2 (en) * | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| CN103415301A (zh) * | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| KR102042982B1 (ko) * | 2011-07-22 | 2019-11-11 | 체에스엘 베링 게엠베하 | 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용 |
| EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| BR112014003787A2 (pt) * | 2011-08-23 | 2020-10-27 | Synapse B.V. | inibidores termoestáveis de ativação do sistema de coagulação sanguínea por contato com superfícies estranhas |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| WO2014089493A1 (en) * | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| JP6636334B2 (ja) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 遠隔虚血再灌流傷害の治療および予防 |
| CA2916399C (en) * | 2013-06-28 | 2022-08-02 | Marc Nolte | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| EP3157548B1 (en) | 2014-06-18 | 2021-08-04 | CSL Behring GmbH | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
| EP4670785A3 (en) | 2015-01-02 | 2026-04-01 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| JP2018521960A (ja) * | 2015-04-28 | 2018-08-09 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤 |
| KR20250054123A (ko) | 2015-07-21 | 2025-04-22 | 다케다 파머수티컬 컴패니 리미티드 | Xiia 인자의 단일클론 항체 저해제 |
| JP7003354B2 (ja) | 2015-12-11 | 2022-03-04 | 武田薬品工業株式会社 | 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途 |
| CN109071629A (zh) * | 2016-04-06 | 2018-12-21 | 杰特有限公司 | 治疗动脉粥样硬化的方法 |
| EP3723804A4 (en) | 2017-12-15 | 2021-10-20 | CSL Limited | USE OF AN FXIIA INHIBITOR IN THE TREATMENT OF KIDNEY FIBROSIS AND / OR CHRONIC KIDNEY DISEASE |
| EA202190056A1 (ru) | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| US12134657B2 (en) | 2018-11-28 | 2024-11-05 | Oregon Health & Science University | Therapeutic factor XII antibody |
| JP7693644B2 (ja) | 2019-07-08 | 2025-06-17 | リゾルート，インコーポレイティド | 血漿カリクレイン阻害薬の調製プロセス |
| JP2023510854A (ja) | 2020-01-13 | 2023-03-15 | 武田薬品工業株式会社 | 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用 |
| WO2021253662A1 (zh) * | 2020-06-16 | 2021-12-23 | 宁波康善生物科技有限公司 | 抗fxii纳米抗体或其抗原结合片段及其应用 |
| TW202242111A (zh) | 2020-12-18 | 2022-11-01 | 美商Ionis製藥公司 | 用於調節因子ｘｉｉ之化合物及方法 |
| WO2025019789A1 (en) | 2023-07-19 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK225488D0 (da) * | 1988-04-26 | 1988-04-26 | Novo Industri As | Polypeptid |
| US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1994020535A1 (en) * | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
| CA2170030A1 (en) | 1993-09-14 | 1995-03-23 | Robert A. Lazarus | Pharmaceutical compositions containing ecotin and homologs thereof |
| ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| US20030109680A1 (en) * | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| DE19725014A1 (de) * | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| ATE274600T1 (de) * | 1998-06-08 | 2004-09-15 | Univ Vermont | Verfahren zur bestimmung der blutgerinnung in plasma |
| AU760735B2 (en) * | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
| ATE468136T1 (de) * | 2001-01-11 | 2010-06-15 | D Collen Res Foundation Vzw | Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion |
| EP2311432B1 (en) * | 2002-06-07 | 2014-12-24 | Dyax Corporation | Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US20060093595A1 (en) | 2002-07-05 | 2006-05-04 | Mahesh Jayachandra | Methods, compositions and kits for treating damage to excitable tissue |
| SI2386310T1 (sl) * | 2002-08-28 | 2019-03-29 | Dyax Corp. | Metode za ohranjanje organov in tkiv |
| US20040229778A1 (en) * | 2003-05-13 | 2004-11-18 | Elmaleh David R. | Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| USRE43691E1 (en) | 2003-05-16 | 2012-09-25 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
| US8152750B2 (en) * | 2003-09-12 | 2012-04-10 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
| GB0411145D0 (en) | 2004-05-19 | 2004-06-23 | Imp College Innovations Ltd | Protease inhibitors and their therapeutic applications |
| US8569277B2 (en) * | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| GB0418877D0 (en) | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
| US20060104944A1 (en) * | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
| DE602004027515D1 (de) | 2004-12-01 | 2010-07-15 | Par Pharmaceuticals Inc | Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz |
-
2005
- 2005-12-20 US US11/793,820 patent/US8119137B2/en active Active
- 2005-12-20 CN CNA2005800465756A patent/CN101102819A/zh active Pending
- 2005-12-20 RU RU2007123797/14A patent/RU2514878C2/ru not_active Application Discontinuation
- 2005-12-20 EP EP05820601A patent/EP1830924B1/en not_active Expired - Lifetime
- 2005-12-20 AU AU2005318464A patent/AU2005318464B2/en not_active Expired
- 2005-12-20 WO PCT/EP2005/013714 patent/WO2006066878A1/en not_active Ceased
- 2005-12-20 BR BRPI0519349A patent/BRPI0519349A8/pt not_active Application Discontinuation
- 2005-12-20 EP EP10183075A patent/EP2272565A3/en not_active Withdrawn
- 2005-12-20 KR KR1020077016992A patent/KR101277097B1/ko not_active Expired - Lifetime
- 2005-12-20 ES ES05820601T patent/ES2407965T3/es not_active Expired - Lifetime
- 2005-12-20 DK DK05820601.2T patent/DK1830924T3/da active
- 2005-12-20 MX MX2007006997A patent/MX2007006997A/es active IP Right Grant
- 2005-12-20 JP JP2007547323A patent/JP5118492B2/ja not_active Expired - Lifetime
- 2005-12-20 CA CA2591786A patent/CA2591786C/en not_active Expired - Lifetime
- 2005-12-20 PL PL05820601T patent/PL1830924T3/pl unknown
-
2011
- 2011-12-29 US US13/339,793 patent/US20120148688A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,847 patent/US8715672B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US8715672B2 (en) | 2014-05-06 |
| PL1830924T3 (pl) | 2013-08-30 |
| DK1830924T3 (da) | 2013-05-21 |
| CN101102819A (zh) | 2008-01-09 |
| KR101277097B1 (ko) | 2013-06-20 |
| JP2008525342A (ja) | 2008-07-17 |
| BRPI0519349A8 (pt) | 2017-09-12 |
| ES2407965T3 (es) | 2013-06-17 |
| KR20070092303A (ko) | 2007-09-12 |
| JP5118492B2 (ja) | 2013-01-16 |
| EP2272565A3 (en) | 2012-03-28 |
| US8119137B2 (en) | 2012-02-21 |
| WO2006066878A1 (en) | 2006-06-29 |
| BRPI0519349A2 (pt) | 2009-01-20 |
| RU2514878C2 (ru) | 2014-05-10 |
| MX2007006997A (es) | 2007-10-10 |
| US20130164301A1 (en) | 2013-06-27 |
| US20080254039A1 (en) | 2008-10-16 |
| AU2005318464A1 (en) | 2006-06-29 |
| EP1830924B1 (en) | 2013-02-27 |
| AU2005318464B2 (en) | 2012-02-23 |
| CA2591786C (en) | 2013-07-16 |
| CA2591786A1 (en) | 2006-06-29 |
| US20120148688A1 (en) | 2012-06-14 |
| EP2272565A2 (en) | 2011-01-12 |
| EP1830924A1 (en) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007123797A (ru) | Предотвращение формирования и/или стабилизации тромбов | |
| JP2008525342A5 (ru) | ||
| Kutsogiannis et al. | Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients | |
| DK175704B1 (da) | Inhibering af arteriel thrombotisk okklusion eller thromboenboli | |
| Smith et al. | How it all starts: Initiation of the clotting cascade | |
| Kenne et al. | Factor XII: a drug target for safe interference with thrombosis and inflammation | |
| Hillmeister et al. | The kallikrein-kinin system. | |
| US20050245488A1 (en) | Pharmaceutically active compounds and methods of use thereof | |
| Mukaiyama et al. | Abdominal aortic aneurysm complicated with chronic disseminated intravascular coagulopathy: a case of surgical treatment | |
| EA013078B1 (ru) | Применение диосметиновых соединений при лечении и профилактике тромботических патологий | |
| Jeske et al. | Pharmacology of argatroban | |
| Espinosa et al. | Vascular involvement in Behçet's disease | |
| Hellstern et al. | Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency | |
| Gomazkov | Damage to the vascular endothelium as a leading mechanism of COVID-19 systemic pathology | |
| Dellalibera-Joviliano et al. | Kinin system in lupus nephritis | |
| Haberland | The role of kininogenases, kinin formation and kininogenase inhibition in post traumatic shock and related conditions | |
| Malyszko et al. | Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients | |
| Marks | Coagulation disorders in the ICU | |
| Sommoggy et al. | Coagulation in aortofemoral bifurcation bypass grafting | |
| Sanchez et al. | Surface-adsorbed fibrinogen and fibrin may activate the contact activation system | |
| Bhagat et al. | Delayed massive pulmonary thromboembolic phenomenon following envenomation by Mojave rattlesnake (Crotalus scutulatus) | |
| Sánchez et al. | On the control of the plasma contact activation system on human endothelium: comparisons with heparin surface | |
| Aasen et al. | Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis | |
| Hill et al. | Acquired heparin‐like anticoagulants: A second case in metastatic breast carcinoma and literature review | |
| Porte et al. | A comparative study on changes in hemostasis in orthotopic and auxiliary liver transplantation in pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101019 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20110812 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20121101 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20131024 |